latest update:
[TrialBase DB]

trial summary · NCT07614022

A Study of LP-118 In Combination With Ponatinib, Dexamethasone And Blinatumomab For Adults With Newly-Diagnosed, BCR::ABL1-Positive Acute Lymphoblastic Leukemia (ALL)

A Phase I Study of the Bcl-2/Bcl-XL Inhibitor LP-118 In Combination With Ponatinib, Dexamethasone And Blinatumomab For Adults With Newly-Diagnosed, Philadelphia-Chromosome/BCR::ABL1-Positive Acute Lymphoblastic Leukemia

Trial record from the TrialBase DB dataset, status RECRUITING, condition Philadelphia Positive Acute Lymphoblastic Leukemia, sponsored by Wake Forest University Health Sciences. Facts below are exported values from the current release, not inferred or edited prose.

registry NCT07614022phase PHASE1enrollment 26start 2026-12

Summary

The brief summary is the registry's published description, capped for length. Field definitions, types, and provenance rules are in the data dictionary.

The purpose of this research study is to see if a drug called LP-118 is safe and effective for treating adults with Philadelphia chromosome-positive (Ph+) B cell acute lymphoblastic leukemia (ALL), when given with ponatinib, dexamethasone, methotrexate and blinatumomab (the standard treatment for this type of cancer).

Source record: https://clinicaltrials.gov/study/NCT07614022

Facts

registry idNCT07614022
primary registryclinicaltrials-gov
recruitment statusRECRUITING
phasePHASE1
study typeINTERVENTIONAL
lead conditionPhiladelphia Positive Acute Lymphoblastic Leukemia
sponsorWake Forest University Health Sciences
sponsor classOTHER
enrollment26
start date2026-12
primary completion2030-03
completion2030-03
results postednot reported

Conditions

  • Philadelphia Positive Acute Lymphoblastic Leukemia

Interventions

  • LP-118

Countries

  • United States

Intervention types: DRUG

Work with this record